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ABSTRACT:
It was shown earlier that the monoterpene ketone, piperitenone (I)
is one of the major metabolites of R-(1)-pulegone, a potent hepa-
totoxin. In the present studies, the metabolic disposition of piperi-
tenone (I) was examined in rats. Piperitenone (I) was administered
orally (400 mg/kg of the b. wt./day) to rats for 5 days. The following
urinary metabolites were isolated and identified by various spectral
analyses: p-cresol (VI), 6,7-dehydromenthofuran (III), p-mentha-
1,3,5,8-tetraen-3-ol (IX), p-mentha-1, 3,5-triene-3, 8-diol (X), 5-hy-
droxypiperitenone (VIII), 7-hydroxypiperitenone (XI), 10-hydroxypi-
peritenone (XII), and 4-hydroxypiperitenone (VII). Incubation of
piperitenone (I) with phenobarbital-induced rat liver microsomes in
the presence of NADPH resulted in the formation of five metabo-
lites which have been tentatively identified as metabolites III, VII,
VIII, XI, XII, on the basis of gas chromatography retention time and
gas chromatography-mass spectrometry analysis. Based on these
results, a probable mechanism for the formation of p-cresol from
piperitenone (I) via the intermediacy of metabolite III has been
proposed.
The hepatotoxicity mediated by pennyroyal oil from Mentha pule-
gium has been attributed to its major constituent, R-(1)-pulegone
(Gordon et al., 1982). This hepatotoxin gets extensively metabolized
in the rat system, and the existence of two major pathways for its
biotransformation has been demonstrated (Moorthy, et al., 1989;
Madyastha and Raj, 1993). One of the major pathways is initiated
through the regiospecific hydroxylation of R-(1)-pulegone to 9-hy-
droxypulegone, which is further transformed to menthofuran (Mad-
yastha and Raj, 1990, Gordon et al., 1987). In the other major
pathway, R-(1)-pulegone is subjected to stereoselective hydroxyla-
tion at C-5 position to form 5-hydroxypulegone, which, upon dehy-
dration, yields piperitenone (I) (Madyastha and Raj, 1993). Most of
the metabolites of R-(1)-pulegone are arising from these two com-
mon intermediates, viz. menthofuran and piperitenone (I). Using a rat
model, it has been estimated that menthofuran accounts for nearly half
the toxicity mediated by R-(1)-pulegone (Thomassen, et al., 1988).
These observations suggest that pulegone elicits toxicity either di-
rectly or through metabolites formed independently of menthofuran.
Because piperitenone (I) is one of the major metabolites of R-(1)-
pulegone (Madyastha and Raj, 1993), it is quite possible that either
piperitenone (I) or metabolites derived from it could also contribute to
the toxicity mediated by R-(1)-pulegone.
It has been reported that S-(2)-pulegone is significantly less toxic
than its R-(1)-enantiomer (Gordon et al., 1982). The only difference
between these two enantiomers is the orientation of the methyl group
at the C-5 position. Comparative metabolic studies carried out using
R-(1) and S-(2)-pulegones have shown that all the major metabolites
isolated and identified from both these enantiomers are the same
(Madyastha and Gaikwad, 1998). However, there is a distinct differ-
ence between these two enantiomers with respect to the relative
amounts of various metabolites formed. These studies have shown
that the level of p-cresol (VI) and piperitenone (I) are significantly
higher in the urine of rats treated with R-(1)-pulegone than of those
treated with S-(2)-pulegone (Madyastha and Gaikwad, 1998). This
suggests that piperitenone (I) could also independently contribute to
R-(1)-pulegone-mediated toxicity. To better understand the mecha-
nism and chemical basis of R-(1)-pulegone-mediated toxicity, meta-
bolic studies with piperitenone (I) were undertaken both in vivo and
in vitro. In fact, there has not been any report on the metabolic fate of
piperitenone (I) in mammals. The present study describes the isolation
and characterization of several novel metabolites from the urine of
rats dosed with piperitenone (I), and some of these metabolites appear
to be hitherto not known. The study also reports a new pathway for the
formation of p-cresol, a known toxin from piperitenone (I).
Materials and Methods
Chemicals. Piperitenone (I) was synthesized as reported earlier (Nakanishi,
et al., 1980) and purified by column chromatography over silica gel using ethyl
acetate/hexane (5:95, v/v) as eluent. The purity of piperitenone used was more
than 99% on the basis of gas chromatography (GC)1 analysis. Glucose 6-phos-
phate, glucose 6-phosphate dehydrogenase, NADP1, methyl cellulose, and
Tris-HCl were supplied by Sigma Chemical Co. (St. Louis, MO). Phenobar-
bital was a generous gift from IDPL (Hyderabad, India).
Animals and Dosing. Adult male rats (Wistar strain) weighing 180 to 200 g
were used in these studies. Piperitenone (I) was administered to rats (n 5 30)
once daily for 5 days (400 mg/kg b. wt.) by gastric intubation as a suspension
in 1% methylcellulose solution (1 ml). Control rats (n 5 5) received only the
vehicle. Control and experimental rats were housed separately in stainless steel
metabolism cages with free access to food (laboratory animal food from Brook
This investigation was financially supported by JNCASR (Bangalore).
1Abbreviations used are: GC, gas chromatography; MS, mass spectrometry;
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Bond and Lipton, India) and water. Urine was collected in bottles maintained
at 0–4°C.
Extraction of Urinary Metabolites. The urine samples collected daily
from control and experimental rats were adjusted to pH 5 to 6 with 1 N HCl
and extracted three times with diethyl ether. The ether extracts for each day
were pooled and stored at 0–4°C. The pooled ether extracts was concentrated
and separated into acid and neutral fractions by extracting with 5% (w/v)
aqueous NaHCO3 solution. The bicarbonate phase was acidified and extracted
with ether to obtain the total acid fraction. The ether extract, following removal
of the acid fraction, contained the neutral/phenolic metabolites.
Preparation of Microsomes. Pretreatment of rats with phenobarbital (80
mg/kg b. wt.) was carried out as reported earlier (Madyastha and Srivatsan,
1987). The livers were minced and homogenized in Tris-HCl (0.05 M, pH 7.4)
containing 0.25 M sucrose, and the microsomes were prepared following the
method of Lu and Levin (1972). Microsomal pellets were suspended in
Tris-HCl buffer (0.05 M, pH 7.8) containing 0.25 M sucrose and 20% glycerol
(v/v) and were stored at 220°C. Protein determinations were conducted
following the method of Lowry et al. (1951).
Studies In Vitro. Phenobarbital-induced rat liver microsomes (2 mg/ml)
were incubated in the presence of glucose 6-phosphate (5 mM), NADP1 (0.5
mM), glucose 6-phosphate dehydrogenase (2 unit), MgCl2 (10 mM), piperi-
tenone (2 mM, in 100 ml of acetone), and Tris-HCl (0.01 M, pH 7.4) in a total
volume of 10 ml. The reaction was initiated by the addition of an NADPH-
generating system, and the mixture was incubated aerobically in a rotary
shaker for 1 h at 37°C. At the end of the incubation period, the assay tubes
were immersed in ice, and the protein was precipitated by adding 4 ml each of
saturated Ba(OH)2 and 0.25 M ZnSO4 solution. The precipitated protein was
removed by centrifugation. The supernatant was extracted three times with 15
to 20 ml of methylene chloride, dried over anhydrous Na2SO4, concentrated,
and an aliquot was subjected to GC and gas chromatography-mass spectrom-
etry (GC-MS) analysis. This experiment was also repeated using uninduced
(control) rat liver microsomes.
Chromatographic Procedures. Thin-layer chromatography (TLC) was
carried out on Silica Gel-G coated plates (0.25 mm) developed with hexane/
ethyl acetate as the solvent system (system 1, 70:30, v/v; system 2, 30:70, v/v;
system 3, 90:10, v/v). Compounds were visualized on the chromatograms by
spraying the TLC plates with 1% vanillin in 50% H2SO4 followed by heating
at 100°C for 5 to 10 min.
GC. Analyses were carried out on a Shimadzu GC model 14A instrument
equipped with a hydrogen flame ionization detector. The instrument was fitted
with a Shimadzu HR-1 wide bore capillary column (15 m 3 0.5 mm diameter).
Nitrogen at a flow rate of 30 ml/min was used as the carrier gas. The
temperature of the column was held at 80°C for 10 min, rising thereafter at
5°C/min to 120°C.
Spectra. Infrared (IR) spectra were recorded on Perkin-Elmer model 781.
Proton NMR spectra were recorded on a JEOL FT-90 MHz spectrometer.
Chemical shifts are reported in ppm, with respect to tetramethylsilane as the
internal standard. Mass spectral analyses were performed on a JEOL-JMX-DX
303 instrument attached with a JMA-DA 5000 data system. A capillary column
(50 m in length and 0.25 mm in diameter) containing either 3% SE-30 on
chromosorb-W or 10% QF1 on chromosorb-W was used for the effective
separation of metabolites. The column temperature was programmed between
60° and 100°C at a rate of 2°C/min, and then to 220°C at 8°C/min. Helium was
used as a carrier gas at a flow rate of 30 ml/min.
Results
Biotransformation of Piperitenone In Vivo. TLC analysis (sys-
tem 1) of neutral/phenolic fraction (2.6 g) showed the presence of at
least nine compounds which were absent in control urine extract. This
fraction (2.6 g) was subjected to column chromatography over neutral
alumina (45 g), and elution of the column with pentane yielded the
least polar metabolite [relative front (Rf) 0.93, system 1, retention
time (Rt) 3.9 min]. This compound had the following spectral char-
acteristics: NMR spectrum (CDCl3, Fig. 1) showed signals at d 7.0
(1H, s, C-2 aromatic proton), 6.05 (1H, bs, C-7 olefinic proton), 2.7 to
2.1 (4H, m, C-4 & C-5 protons), 1.9 (3H, s, methyl protons on furan
ring), and 1.85 (3H, s, C-8 methyl protons). Mass spectra (MS) (Fig.
1, inset) were: m/z 148(M1), 133(M1-CH3), 105(M1-C2H3O, base
peak), and 91(M1-C3H5O). Based on these spectral characteristics,
the compound was tentatively assigned the structure 6,7-dehydrom-
enthofuran (III, Fig. 2). This compound is unstable, and upon storage,
it transformed into another compound with a mass spectral fragmen-
tation pattern that corresponded well with that reported for 3,6-
dimethyl benzofuran (Givens, et al., 1969) (Fig. 3). Formation of
3,6-dimethyl benzofuran from metabolite III further supports the
structure assigned to the least polar metabolite (III) as 6,7-dehydro-
menthofuran.
Additional elution of the column with hexane yielded a fraction that
upon GC (Rt 4.0 and 8.1 min) and TLC (system 1, Rf 0.66 and 0.57)
analyses showed the presence of two major compounds. These two
compounds were separated by preparative TLC (system 3). The com-
pound with Rf 0.66 and Rt 4.0 min showed the following spectral
characteristics: NMR spectra (CDCl3, Fig.4) d 7.1 to 6.7 (2H, two
doublets, C-5 & C-6 aromatic protons), 6.75 (1H, s, C-2 aromatic
proton), 5.7 (1H, bs, hydroxyl proton), 5.4 (1H, bs, C-9a olefinic
proton), 5.15 (1H, bs, C-9b olefinic proton), 2.3 (3H, s, methyl
protons on aromatic ring), and 2.1 (3H, s, allylic methyl proton). IR
(neat) spectrum showed absorptions around 3500 cm-1 (hydroxyl
group) and 1620 cm-1 (aromatic). Mass Spectra (Fig. 4, inset) were:
m/z 148(M1), 133(M1-CH3), 119(M1-C2H5), 105(M1-C3H7), and
43(M1-C7H5O, base peak). Based on the spectral data the compound
was identified as p-mentha-1, 3,5,8-tetraen-3-ol (IX, Fig. 2). The
structure assigned was also confirmed by comparing the spectral
characteristics (NMR and IR) with that reported for this compound
(Divakar, et al., 1977).
The compound with Rf 0.57 was identified as unmetabolized piper-
itenone (I) by comparing its GC retention time (Rt 8.1 min) and NMR,
IR and mass spectra with that of authentic compound.
The metabolite with Rf 0.56 (system 1) was eluted from the neutral
alumina column with 19:1 hexane/ethyl acetate. The metabolite was
identified as p-cresol (VI) by comparing its spectral data [NMR, IR,
and mass spectrometry (MS)] to that reported earlier (Madyastha and
Raj, 1992). Further elution of the column with the same solvent
system yielded a compound with Rf 0.5 (system 1) and Rt 12.3 min.
This compound had the following spectral characteristics. IR spec-
trum (neat) showed absorptions at 3300 cm-1 (hydroxyl group), 1570
cm-1 and 1620 cm-1 (aromatic ring). NMR spectra (CDCl3, Fig. 5)
were: d 8.9 (1H, bs, phenolic hydroxyl), 6.97 to 6.61 (2H, two
FIG. 1. 1HNMR spectra and electron impact mass spectra (inset) of
6,7-dehydromenthofuran (III).
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doublets, C-5 and C-6 aromatic protons), 6.68 (1H, s, C-2 aromatic
proton), 2.24 (3H, s, methyl on aromatic ring), and 1.65 (6H, s,
dimethyl group on C-8). MS analysis showed molecular ion peak at
m/z 166 and fragmentation pattern (Fig. 5, Inset) m/z 166(M1),
148(M1-H2O, base peak), 133(M1-CH5O) and 105 (M1-C3H9O).
Based on the spectral characteristics, the metabolite was identified as
p-mentha-1, 3,5-triene-3, 8-diol (X, Fig. 2) The spectral characteris-
tics of metabolite X agreed with the earlier report on this compound
(Desai, et al., 1984).
Elution of the column with hexane/ethyl acetate (9:1, v/v) yielded
a compound having Rf 0.6 (system 2) and Rt 15.9 min. The compound
had the following spectral characteristics. NMR spectra (CDCl3, Fig.
6) were: d 5.9 (1H, s, olefinic proton), 4,27 (1H, m, C-5 proton), 2.87
(2H, m, C-4 methylene protons), 2.15 (3H, s, C-9 methyl protons),
2.04 (3H, s, C-7 methyl protons) and 1.9 (3H, s, C-10 methyl protons).
IR spectrum (neat) showed absorptions at 3380 cm-1 (hydroxyl
group), 1650 cm-1 (conjugated ketone), and 1600 cm-1 (double bond).
Mass spectra (Fig. 6, inset) were: m/z 166(M1, base peak), 151(M1-
CH3), 148(M1-H2O), 123(M1-C2H3O), and 108(M1-C3H6O). Based
on these spectral characteristics, the compound was assigned the
structure 5-hydroxypiperitenone (VIII, Fig. 2).
The metabolites with Rf 0.5 (system 2) and Rt 20.5 min was eluted
from the neutral alumina column with 8:2 hexane/ethyl acetate. The
compound had the following spectral characteristics: IR spectrum
(neat) showed absorptions at 3380 cm-1 (hydroxyl group), 1650 cm-1
(conjugated ketone) and 1600 cm-1 (double bond). NMR spectra
(CDCl3, Fig. 7) d 6.1 (1H, s, olefinic proton), 4.2 (2H, bs, C-7
protons), 2.7 (2H, t, C-4 protons), 2.25 (2H, t, C-5 protons), 2.1 (3H,
s, C-9 methyl protons) and 1.85 (3H, s, C-10 methyl protons). Mass
spectra (Fig. 7, inset) were: m/z 166(M1, base peak), 137(M1-C2H5),
135(M1-CH2OH), 123(M1-C2H3O), and 109(M1-C3H5O). From the
spectral data, the metabolite was identified as 7-hydroxypiperitenone
(XI, Fig. 2).
Additional elution of column with 8:2 hexane/ethyl acetate gave a
fraction that upon GC analysis showed the presence of two com-
pounds (Rt 19.2 and 15.8 min). The TLC analysis (system 2) of this
FIG. 2. Probable metabolic pathways of piperitenone (I).
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fraction revealed the presence of two compounds (Rf 0.47 and 0.42)
which were separated by repeated preparative TLC (system 2). The
compound with Rf 0.47 showed the following spectral characteristics:
IR spectrum (neat) showed absorption at 3375 cm-1 (hydroxyl group),
1645 cm-1 (conjugated ketone), and 1600 cm-1 (double bond). NMR
spectra (CDCl3, Fig. 8) were: d 5.92 (1H, s, olefinic proton), 4.25 (2H,
s, C-10 protons), 2.82 (2H, t, C-4 protons), 2.35 (2H, t, C-5protons),
2.11 (3H, s, C-9 methyl protons), and 1.93 (3H, s, C-7 methyl
protons). Mass spectra (Fig. 8, inset) were: m/z 166(M1, base peak),
148(M1-H2O), 147(M1-H3O), 133(M1-CH5O) and 105(M1-
C3H9O). Based on the spectral data, the compound was identified as
10-hydroxypiperitenone (XII, Fig. 2). The compound with Rf 0.42
(system 2) and Rt 15.8 min showed the following spectral properties:
IR spectrum (liquid film) showed absorption at 3385 cm-1 (hydroxyl
group), 1650 cm-1 (conjugated ketone), and 1590 cm-1 (double bond).
NMR spectrum (CDCl3, Fig. 9) d 5.98 (1H, s, olefinic proton), 5.1
(1H, m, C-4 proton), 2.58 (2H, bs, C-5 proton), 2.14 (3H, s, C-9
methyl protons), and 1.98 (6H, s, C-10 and C-7 methyl protons). Mass
spectra (Fig. 9, inset) were: m/z 166(M1, base peak), 149(M1-OH),
151(M1-CH3), 137(M1-C2H5), 133(M1-CH5O), 123(M1-C2H3O),
and 109(M1-C3H5O). From the spectral data, the metabolite was
identified as 4-hydroxypiperitenone (VII, Fig. 2).
The composition of the total neutral/phenolic fraction (Fig. 10) was
FIG. 3. Electron impact mass spectra of 3,6-dimethylbenzofuran.
FIG. 4. 1HNMR spectra and electron impact mass spectra (inset) of
p-mentha-1,3,5,8-tetraen-3-ol (IX).
FIG. 5. 1HNMR spectra and electron impact mass spectra (inset) of
p-mentha-1,3,5-triene-3, 8-diol (X).
FIG. 6. 1HNMR spectra and electron impact mass spectra (inset) of
5-hydroxypiperitenone (VIII).
FIG. 7. 1HNMR spectra and electron impact mass spectra (inset) of
7-hydroxypiperitenone (XI).
77BIOTRANSFORMATION OF PIPERITENONE IN RATS
determined by GC analyses. The analyses showed the presence of
seven major peaks corresponding to metabolites III, VI, VII, VIII,
IX, X, XI, and XII and unmetabolized piperitenone (I) (Fig. 2). GC
profile also showed few minor peaks, which could not be identified.
The peaks corresponding to these metabolites (III, VI, VII, VIII, IX,
X, XI, and XII) were enhanced when mixed with the purified metab-
olites isolated by column chromatography. On the basis of GC anal-
ysis, nearly 85% of the total neutral/phenolic fraction was identified.
Two pairs of metabolites (III and IX; VII and VIII) could not be
separated well under the GC conditions used.
Acidic Metabolites. Very little acidic fraction was obtained, and it
did not contain any metabolites derived from piperitenone. Hence this
fraction was not processed further.
Biotransformation of Piperitenone (I) by Liver Microsomes.
Phenobarbital-induced rat liver microsomes were incubated with pi-
peritenone (I) in the presence of NADPH and O2 as described in
Materials and Methods. The methylene chloride extract of the assay
mixture upon GC analysis indicated the presence of metabolites VII,
VIII, XI, XII and III. All of the peaks corresponding to these
metabolites were enhanced when mixed with samples isolated by
column chromatography. The GC-MS analysis of the assay mixture
indicated the presence of metabolites VII, VIII, XI, XII and III.
Nearly 10% of the substrate (I) added was converted into these five
metabolites (VII, VIII, XI, XII and III). Among the metabolites
formed, compound III was present in higher levels. Incubation of
piperitenone (I) with uninduced (control) rat liver microsomes in the
presence of NADPH and O2 as described in Materials and Methods,
FIG. 8. 1HNMR spectra and electron impact mass spectra (inset) of
10-hydroxypiperitenone (XII).
FIG. 9. 1HNMR spectra and electron impact mass spectra (inset) of
4-hydroxypiperitenone (VII).
FIG. 10. The GC analysis of the total neutral/phenolic fraction.
Analysis was carried out as described in Materials and Methods. Roman numbers
represent the different metabolites. Two pairs of metabolites (III and IX and VII
and VIII) do not separate under the GC conditions employed. The structure of the
metabolites, their retention time and percentage composition are presented. Purified
metabolites III, IX, VIII and VII have the retention time as 3.9, 4.0, 15.9and 15.8
min respectively. However, when the total neutral/phenolic fraction was injected,
metabolite pairs III and IX and VIII and VII have retention time (Rt) as 3.98 and
15.9 min, respectively.
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and GC analysis of the methylene chloride extract of the reaction
mixture indicated that metabolites were present in very low amounts.
Discussion
The present study has demonstrated the ability of the rat’s system
to carry out various transformations in piperitenone (I). Most of the
metabolites present in the urine of rats dosed with piperitenone (I)
have been isolated and characterized based on various spectral anal-
yses. It is interesting to note that all of the five positions in piperi-
tenone (I) which are allylic to double bonds are hydroxylated, unlike
in R-(1)-pulegone (Madyastha and Raj, 1993). Cursory examination
of different metabolites isolated from the urine extract indicated the
existence of two major pathways (A and B, Fig. 2) for the biotrans-
formation of I. However, it should be noted here that the pathways
proposed are speculative and certainly need more experimental evi-
dence to substantiate the sequence of reactions. Suitable experimental
precautions were taken to minimize the loss and nonenzymatic trans-
formations of the metabolites during their isolation.
Pathway A (Fig. 2) appears to be the most interesting and signifi-
cant, as it is involved in the formation of p-cresol (VI, Fig. 2). It has
been reported earlier that p-cresol (VI) causes severe toxicity in both
liver and lung (Deichmann and Keplinger, 1958; US Department of
Health, 1992; Thompson et al., 1994). It (VI) is also one of the major
metabolites of R-(1)-pulegone and menthofuran in vivo (Madyastha
and Raj, 1992, 1993). It appears that the first step in pathway A in the
biotransformation sequence (Fig. 2) is the oxygenation of the C-9
methyl group, resulting in the formation of 9-hydroxypiperitenone
(II), which upon cyclization followed by dehydration yields 6,7-
dehydromenthofuran (III). The fact that this metabolite (III) is un-
stable and gets converted to 3,6-dimethylbenzofuran (Fig. 3) lends
further support to the structure assigned to this metabolite as 6,7-
dehydromenthofuran (III). Studies carried out in vitro using pheno-
barbital-induced rat liver microsomes gave corroborative experimen-
tal evidence for the above sequence of reactions. In fact, the sequence
of reactions involved in the formation of 6,7-dehydromenthofuran
(III) appears to be very similar to the earlier reports on the formation
of menthofuran from R-(1)-pulegone (Gordon et al., 1987; Madyas-
tha and Raj, 1990). One can envisage the formation of p-cresol (VI)
from 6,7-dehydromenthofuran (III) as shown in Fig. 2. The liver
microsomal cytochrome P-450 system can convert compound III to
its 2,3-epoxide, and opening of the epoxide can give rise to an
unsaturated ketoaldehyde (IV, Fig. 2). Reduction of the keto group in
IV to a secondary alcohol and its elimination would generate 1,2-
double bond with a simultaneous migration of the 2,3-double bond to
3,4-position. This sequence of reaction is followed by hydration of the
exocyclic double bond (V, Fig. 2) which facilitates a spontaneous
nonezymatic retroaldol type reaction to yield p-cresol (VI, Fig. 2).
The proposed catabolic sequence (Fig. 2) appears to be analogous to
the pathway established earlier for the conversion of menthofuran to
p-cresol via the intermediacy of an a,b-unsaturated-g-ketoaldehyde
(McClanahan et al., 1989; Madyastha and Raj, 1990, 1992). Earlier
studies have shown that rat liver microsomes in the presence of
NADPH and O2 convert menthofuran to an highly reactive a,b-
unsaturated-g-ketoaldehyde which interacts with tissue macromole-
cules to elicit toxicity (Madyastha and Moorthy, 1989; McClanahan et
al., 1989; Madyastha and Raj, 1990). Alternatively, this reactive
metabolite is further transformed to 4-methyl-2-cyclohexenone, which
yields p-cresol upon hydroxylation (Madyastha and Raj, 1991, 1992).
In fact, mechanistically, the conversion of 6,7-dehydromenthofuran
(III) to p-cresol (VI) appears to be comparatively simpler than the
transformation of menthofuran to p-cresol (VI) due to the presence of
6,7-double bond in compound III (Fig. 2). The sequence of reactions
postulated in the conversion of III to p-cresol (VI) could not be tested
in vitro using 6,7-dehydromenthofuran (III), as this compound ap-
pears to be unstable and all attempts to synthesize it were not suc-
cessful.
The most interesting aspect of pathway A (Fig. 2) is that it repre-
sents a new route for the formation of p-cresol (VI) from R-(1)-
pulegone via the intermediacy of piperitenone (I) and 6,7-dehydrom-
enthofuran (III). Earlier studies have clearly established that
piperitenone is one of the metabolites of R-(1)-pulegone in vivo
(Madyastha and Raj, 1993). It is quite possible that the metabolites
such as p-cresol (VI), 6,7-dehydromenthofuran (III) formed via path-
way A may also contribute toward the pulegone-mediated toxicity in
mammals. In fact, it has been shown that p-cresol rapidly depletes
intracellular glutathione levels (Thompson et al., 1994). Because
p-cresol (VI) is one of the major metabolites formed from both
R-(1)-pulegone and menthofuran in vivo, it is reasonable to assume
that it (VI) could contribute to the overall toxicity mediated by
R-(1)-pulegone by decreasing the availability of glutathione for con-
jugation with reactive metabolites derived from R-(1)-pulegone. In
support of this argument, Thomassen and his coworkers have shown
that R-(1)-pulegone depletes glutathione in vivo and oxidative me-
tabolites of pulegone are responsible for the glutathione depletion
(Thomassen, et al., 1990). Alternatively, p-cresol can be further trans-
formed either to an epoxide or to a quinone methide as reactive
intermediates which can generate toxic effects by interacting with
tissue macromolecules (Thompson et al., 1994).
The present study has demonstrated that in piperitenone (I) both of
the isopropylidene methyl groups (C-9 and C-10) are hydroxylated as
evidenced by the isolation of 10-hydroxypiperitenone (XII) and 6,7-
dehydromenthofuran (III). The 9-hydroxypiperitenone (II) formed
readily undergoes intramolecular cyclization followed by dehydration
to yield compound III. However, such a cyclization is not possible in
the case of 10-hydroxypiperitenone (XII). These results are supported
by the in vitro studies carried out using phenobarbital-induced rat liver
microsomes. Contrary to these observations, it was noted that in the
case of R-(1)-pulegone only the methyl group syn to the carbonyl
group is hydroxylated by the liver microsomal cytochrome P-450
system (Gordon et al., 1987; Madyastha and Raj, 1990).
Pathway B for the biodegradation of piperitenone (I) is initiated
through ring hydroxylation resulting in the formation of 4-hydroxy
(VII) and 5-hydroxy (VIII) piperitenones (Fig. 2). Both of these
compounds (VII and VIII), upon dehydration, could yield compound
IX (Fig. 2). Hydration of the exocyclic double bond in compound IX
could yield metabolite X (Fig. 2). Metabolite XI (Fig. 2) might have
been formed through allylic methyl (C-7 methyl) hydroxylation. Di-
rect hydroxylation of piperitenone at the C4, C5, C7, and C10 positions
is amply supported by the in vitro studies conducted using phenobar-
bital-induced rat liver microsomes in the presence of NADPH and O2.
In fact, studies carried out in vitro also suggested the possible in-
volvement of phenobarbital-induced cytochrome P-450 system in the
hydroxylation reaction because uninduced (control) liver microsomes
very poorly transformed piperitenone to various metabolites. How-
ever, this observation needs additional experimental support.
In summary, we have demonstrated that p-cresol (VI) is one of the
major metabolites of piperitenone in vivo. Earlier studies have clearly
shown that both piperitenone (I) and menthofuran are the major
metabolites of R-(1)-pulegone in vivo (Madyastha and Raj, 1993).
Hence, it can be inferred that both of these metabolites of R-(1)-
pulegone are independently further biotransformed to p-cresol (VI).
This is a significant observation from the toxicological point of view.
We have proposed the sequence of reactions that can lead to the
formation of p-cresol (VI) from piperitenone (I) via the intermediacy
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of 6,7-dehydromenthofuran (III) and an unsaturated ketoaldehyde
(IV, Fig. 2). This hypothetical scheme is based on chemical logic and
the earlier report on the conversion of menthofuran to an a,b-unsat-
urated-g-ketoaldehyde, by studies carried out in vivo and in vitro
(McClanahan et al., 1989, Madyastha and Raj, 1990, 1992 ).
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